
Get exclusive money-saving offers and guides
Straight to your inbox
Updated
We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Pro Medicus Limited is a health information services business based in Australia. Pro Medicus shares (PME) are listed on the Australian Securities Exchange (ASX) and all prices are listed in Australian Dollars. Pro Medicus has a trailing 12-month revenue of around $56.8 million..
Our top pick for
US stocks
Our top pick for
Cheap broker fees
Our top pick for
Long-term investing
52-week range | $14.4661 - $43.95 |
---|---|
50-day moving average | $32.7676 |
200-day moving average | $28.8904 |
Target price | $9.96 |
PE ratio | 198.6426 |
Dividend yield | $0.12 (0.28%) |
Earnings per share (TTM) | $0.221 |
Standard brokerage - Australian shares
Competitive broker fees on Australian and international shares
Important: Share trading carries risk of capital loss.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the close of A$34.12 on 2020-10-22
1 week (2021-01-14) | -6.60% |
---|---|
1 month (2020-12-24) | -1.30% |
3 months (2020-10-23) | 1.46% |
6 months (2020-07-24) | 43.36% |
1 year (2020-01-23) | 31.33% |
---|---|
2 years (2019-01-23) | 163.47% |
3 years (2018-01-23) | 304.27% |
5 years (2016-01-22) | 962.93% |
Valuing Pro Medicus stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Pro Medicus's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Pro Medicus's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 199x. In other words, Pro Medicus shares trade at around 199x recent earnings.
That's relatively high compared to, say, the P/E ratio for the ASX over the 12 months to December 2019 (32.14). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
Pro Medicus's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $30.3 million (£0.0 million).
The EBITDA is a measure of a Pro Medicus's overall financial performance and is widely used to measure a its profitability.
Revenue TTM | $56.8 million |
---|---|
Operating margin TTM | 52.91% |
Gross profit TTM | $56.5 million |
Return on assets TTM | 20.89% |
Return on equity TTM | 42.16% |
Profit margin | 40.61% |
Book value | 0.579 |
Market capitalisation | $4.6 billion |
TTM: trailing 12 months
Dividend payout ratio: 52.17% of net profits
Recently Pro Medicus has paid out, on average, around 52.17% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0.28% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Pro Medicus shareholders could enjoy a 0.28% return on their shares, in the form of dividend payments. In Pro Medicus's case, that would currently equate to about A$0.12 per share.
Pro Medicus's payout ratio would broadly be considered high, and as such this stock could appeal to those looking to generate an income. Bear in mind however that companies should normally also look to re-invest a decent amount of net profits to ensure future growth.
The latest dividend was paid out to all shareholders who bought their shares by 10 September 2020 (the "ex-dividend date").
Over the last 12 months, Pro Medicus's shares have ranged in value from as little as $14.4661 up to $43.95. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (AU average) beta is 1, while Pro Medicus's is 0.5332. This would suggest that Pro Medicus's shares are less volatile than average (for this exchange).
Pro Medicus Limited provides radiology information systems (RIS), picture archiving and communication systems (PACS), and advanced visualization solutions in Australia, Europe, and North America. It offers medical software for practice management; integration products; Promedicus.net secure email; healthcare software that provides radiologist and clinicians with advanced visualization capability for viewing 2-D, 3-D, and 4-D medical images; and PACS/Digital imaging software. The company offers its products under the Visage RIS, Visage RIS/PACS, and Visage 7 names. It also provides Visage Ease Pro, a mobile applications, which allow users access to medical imaging results that are stored on a Visage 7 server; training, installation, and professional services; and after sale support and service products. The company offers its products and services to hospitals, diagnostic imaging groups, and other health related entities. Pro Medicus Limited was founded in 1983 and is headquartered in Richmond, Australia.
Steps to owning and managing Vanguard Australian Fixed Interest Index ETF units.
Steps to owning and managing Vanguard Ethically Conscious Global Aggregate Bond Index (Hedged) ETF units.
Steps to owning and managing ETFS Morningstar Global Technology ETF units.
Steps to owning and managing BetaShares Global Quality Leaders (Currency Hedged) ETF units.
Steps to owning and managing ETFS ROBO Global Robotics and Automation ETF units.
Steps to owning and managing ETFS FANG+ ETF units.
Steps to owning and managing ETFS S&P Biotech ETF units.
Steps to owning and managing ETFS Reliance India Nifty 50 ETF units.
Steps to owning and managing BetaShares India Quality ETF units.